SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA
  • February 7, 2021
A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade...
Read More
PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
  • February 6, 2021
A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration...
Read More
INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA
  • February 5, 2021
A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to...
Read More
ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA
  • February 4, 2021
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection...
Read More
RIBOCICLIB FOR RECURRENT GLIOBLASTOMA
  • February 3, 2021
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection
Read More
RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT HIGH-GRADE GLIOMA
  • February 1, 2021
A Phase 0/2 study of ribociclib in combination with everolimus in preoperative Rb-intact recurrent high-grade glioma patients scheduled for resection
Read More